Evotec und Crohn´s & Colitis Foundation gehen Vereinbarung zur Förderung der Wirkstoffforschung für neue IBD Therapien ein
. - EVOTEC SCHLIESST SICH MIT DEM IBD THERAPEUTICS INCUBATOR PROGRAMM DER CROHN’S & COLITIS FOUNDATION ZUSAMMEN, UM DIE…
. - EVOTEC SCHLIESST SICH MIT DEM IBD THERAPEUTICS INCUBATOR PROGRAMM DER CROHN’S & COLITIS FOUNDATION ZUSAMMEN, UM DIE…
CONARIS Research Institute AG, a biotechnology company based in Kiel, Germany, announced today that its fusion protein o…
Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunolo…
Phase 3 Program of IMU-838 in Relapsing-Remitting Multiple Sclerosis Expected to Begin in the Second Half of 2021 Repor…
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunol…
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral thera…
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral thera…
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral thera…
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral thera…
. – Unblinded Data Review Committee Recommended Continuation of the Lowest, 10 mg Dose as well as the Highest, 45 mg Dos…